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AJ adherens junction  
AEBSF 4- 2-aminoethyl benzenesulfonyl fluoride hydrochloride 
DAMPs damage-associated molecular patterns 
HDM house dust mite 
ILC2 group 2 innate lymphoid cell 
LPS-RS lipopolysaccharide from Rhodobacter sphaeroides 
NRF1 nuclear respiratory factor 1 
PAMPs pathogen-associated molecular patterns 
PAR protease activated receptor 
PGC-1 peroxisome proliferator-activated receptor γ coactivator-1α 
PRRs pattern-recognition receptors 
TEER transepithelial electrical resistance 
TFAM mitochondria transcription factor A 
TJ tight junction 
TLR Toll-like receptor 








house dust mite ; HDM (BEAS-2B )
PGC-1 adherens junction tight junction
E-cadherin zonula occludens-1 ZO-1 western blot
HDM
PGC-1
SRT1720 protease activated receptor PAR 2
GB83 Toll-like receptor TLR 4 lipopolysaccharide 
 4 
from Rhodobacter sphaeroides LPS-RS
E64  4- 2-aminoethyl benzenesulfonyl fluoride 

















inhaled corticosteroid ; ICS 2
long acting 2 agonist ; LABA
leukotriene receptor antagonist ; LTRA
long acting muscarinic antagonist ; LAMA oral 













PRRs pathogen-associated molecular patterns PAMPs
damage-associated molecular patterns DAMPs IL-25
IL-33 thymic stromal lymphopoietin TSLP
2 κ group 2 innate lymphoid cell ; ILC2 2
3  
house dust mite ; HDM
4 5 zonula occludens-1 ZO-1
tight junction ; TJ E-cadherin / -




protease activated receptor PAR 2 Toll-like receptor
 7 
TLR 4 PRRs κ 2
11 12 13  
 
ADMA asymmetric 
dimethylarginine ; eNOS inhibitor IL-4
peroxisome proliferator-activated receptor γ coactivator-1α
PGC-1α DNA mitochondrial transcriptional 









PGC-1α nuclear respiratory factor 1 NRF1 TFAM
PGC-1 β adenosine 5'-monophosphate-	











AMPK PGC-1 superoxide dismutase
SOD
 21 (chronic obstructive pulmonary 
disease ; COPD) body mass index BMI 21 COPD
PGC-1 mRNA TFAM  
22  23  24
 25  
PGC-1
 26 SIRT1 SRT1720 β
PGC-1 27 SRT1720
COPD LPS
COPD SRT1720 IL-8 IL-6
tumor necrosis factor- TNF-


























American Type Culture Collection Manassas, VA γ
25mg ± 2.5µg
Keratinocytes Supplements Gibco, Grand Island, NY Keratinocyte-
SFM Gibco, Grand Island, NY 37 5%CO2
90%  
Lonza
Wokingham, UK bronchial epithelial basal medium
BEGM Lonza Japan Bioscience, Tokyo, Japan ±
0.5 ng/ml 5 µg/ml 10 µg/ml
0.5 µg/ml 6.5 µg/ml
0.5 µg/ml 50 nM 50 µg/ml
B 50 µg/ml γ 35 mg/ml Bronchial epithelial 




n=4 transepithelial electrical resistance ; TEER
 
 
2 Western blot  
PGC-1 NRF TFAM Western 
blot BEAS-2B
HDM 0 – 200
g/ml, LSL, Tokyo, Japan
PGC-1 TFAM AJ E-cadherin TJ ZO-1
Western blot 6 90%
Keratinocytes Supplements
Keratinocyte-SFM 24 HDM
PGC-1 SRT1720 0 – 1µM, 
Selleck Chemicals, Houston, TX HDM 6 PAR2
GB83 0 – 10mM, Axon Medchem, Groningen, Netherlands TLR4
Lipopolysaccharide from the photosynthetic bacterium Rhodobacter 
sphaeroides LPS-RS 0 – 3µg/ml, Invivogen, San Diego, CA
 14 
E64 0, 50µM, Sigma-Aldrich, St Louis, MO
4- 2-Aminoethyl benzenesulfonyl fluoride 
hydrochloride AEBSF 0 – 100µM, Sigma-Aldrich, St Louis, MO HDM
30 0 – 10-5M, Sigma-
Aldrich, St Louis, MO HDM 24 2
SRT1720 dimethyl sulfoxide DMSO
DMSO 0.1  
0.02% HDM 24
0.05% TritonX, 35mM Tris-HCl, pH7.4 0.4mM EGTA, 10mM MgCl2, 1
M phenylmethylsulfonyl fluoride, 100 g/ml aprotinin, 1 g/ml leupeptin 100
l 5 4
14,000rpm 10 2-
Laemmli Bio-Rad, Hercules, CA 5
12%
PVFD Millipore, Darmstadt, Germany
TOYOBO, Osaka, Japan 60
1 TFAM 1:5000, abcam, 
Cambridge, UK PGC-1 1:5000, abcam, 
Cambridge, UK E-cadherin 1:10000, abcam, 
 15 
Cambridge, UK ZO-1 1:2000, abcam, 
Cambridge, UK 1:5000, Sigma-
Aldrich, St Louis, MO 4 2 Horse Radish 
Peroxidase HRP IgG 1:5000, Santa Cruz 
Biotechnology, Dallas TX HRP IgG 1:5000, 
Santa Cruz Biotechnology, Dallas TX 60
ECL Prime Amersham BioSciences, Buckinghamshire, UK LAS-
4000 mini FUJIFILM, Tokyo, Japan




BEAS-2B 8  1 × 105/ml 300 l
37 5 CO2 24 Keratinocytes Supplements
Keratinocyte-SFM 24 SRT1720 1 M
6 HDM 100 g/ml 24
MitoTracker Red probe 200nM Invitrogen Life Technologies , Eugene, OR
30 4% 30
 16 
0.1 % Triron X-100 10
Dako Japan, Kyoto, Japan 30
1 E-cadherin 1:500
ZO-1 1:200 4 2
fluorescein isothiocyanate FITC IgG abcam, 
Cambridge, MA 1 Hoechst 33342
1:2000, Invitrogen Life Technologies, Eugene, OR
Nikon ECLIPSE Ti-E, C2si; Nikon, Tokyo, Japan




electrical resistance ; TEER TEER
32 33
12
 1 105cells/cm2 BEGM
SRT1720 1 M 24
HDM 100 g/ml 24 Millicell ERS-2 





8 C57BL/6J Kanagawa, Japan
 
34 1 HDM
30µg/50 l ITEA , Tokyo, Japan phosphate buffered saline PBS ; 









Tokyo Japan 60 1
TFAM 1:10000
 18 
PGC-1 1:1000 E-Cadherin 1:10000
4 2 Alexa Fluor
1:3000, abcam, Cambridge, MA 60
BX53 Olympus, Tokyo, Japan
DP71 Olympus, Tokyo, Japan




one way analysis of variance ANOVA Tukey's 
multiple comparison test p<0.05








NRF1 TFAM western blot
PGC-1 NRF1 TFAM PGC-1α, p < 0.05; 
NRF1, p < 0.05; TFAM, p < 0.05 4  
 
2 HDM BEAS-2B AJ
TJ  
HDM BEAS-2B
PGC-1 TFAM E-cadherin ZO-1 western blot
TFAM HDM 100 g/ml
p<0.01 200 g/ml p<0.01 5A
HDM 12 24 48 TFAM p<0.01 24
 20 
5B BEAS-2B
HDM HDM 100 g/ml HDM 24
 
TFAM p<0.01 PGC-1 p<0.01 E-cadherin




PGC-1 TFAM E-cadherin PBS
HDM PGC-1 p<0.01 TFAM
p<0.01 E-cadherin p<0.01 6A-D  
 
 HDM  
1 SRT1720  
SRT1720 BEAS-2B
HDM PGC-1 TFAM E-cadherin western blot
1 M SRT1720 HDM PGC-1
p<0.01 7A SRT1720
 21 
1 M PGC-1 TFAM E-cadherin
HDM SRT 1720 PGC-1 ; p<0.05, 
TFAM ; p<0.05, E-cadherin ; p<0.05 7B-D  
SRT 1720 HDM BEAS-2B E-
cadherin ZO-1 HDM E-
cadherin ZO-1 SRT 1720 E-cadhein ; p<0.05, 
ZO-1 ; p<0.01 8A-D HDM
SRT 1720 p<0.01 8A, B, E  
SRT1720 SRT1720
HDM TEER
TEER HDM p<0.05 SRT1720
p<0.01 7E  
 
2 PAR2 TLR4  
HDM LPS TLR4 PAR2
11 HDM
PGC-1 PAR2
GB83 TLR4 LPS-RS GB83 10 M
HDM PGC-1 E-cadherin ZO-1 ×
 22 
PGC-1 ; p<0.01, E-cadherin ; p<0.05, ZO-1 ; p<0.01 9A-C
LPS-RS 3 g/ml HDM PGC-1 E-cadherin ZO-








AEBSF E64 50 M HDM
PGC-1 E-cadherin × PGC-1 ; p<0.05, E-cadherin ; 
p<0.05 10A, B AEBSF 100 M HDM
PGC-1 E-cadherin × PGC-1 ; p<0.05, E-










































PAR2 TLR4 HDM PAR2 TLR4
PGC-1 E-cadherin ZO-1
μ PAR2 TLR4 HDM BEAS-




Synthetic agonist peptides (AP) TLR LPS
PAR2 TLR4 NF- B
43 PAR2
LPS PAR2/TLR4 IL-
12p40 44 PAR2 TLR4







PGC-1 E-cadherin × PAR2 TLR4
HDM
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NRF1 TFAM western blot




AJ TJ  
A HDM BEAS-2B TFAM
western blot n=3 B
HDM BEAS-2B TFAM time course
western blot n=3 C-
F  HDM BEAS-2B PGC-1 TFAM E-cadherin
ZO-1 western blot n=3




A  HDM PBS C57BL/6J
PGC-1 TFAM E-cadherin
 40 
100 m B-D A
n=3 **p < 0.01 PBS  
 
7  Western blot TEER HDM
PGC-1 SRT1720  
A SRT1720 vehicle HDM BEAS-2B
PGC-1 western blot
n=3 B-D SRT1720 vehicle HDM













m C D E A B




AJ TJ PAR2 GB83
TLR4 LPS-RS  
 A-C GB83 vehicle HDM BEAS-2B
PGC-1 E-cadherin ZO-1 western blot
n=4 D-F LPS-RS vehicle
HDM BEAS-2B PGC-1 E-cadherin ZO-1
western blot LPS-RS n=3





 AEBSF  
 42 
 A B E64 vehicle HDM BEAS-2B
PGC-1 E-cadherin western blot
n=4 C D AEBSF vehicle
HDM BEAS-2B PGC-1 E-cadherin western 
blot n=4 *p < 0.05, 
**p < 0.01 vehicle control  
 
11  BEAS-2B AJ
 
A-C vehicle BEAS-2B
PGC-1 TFAM E-cadherin western blot
n=3 D-F vehicle
HDM BEAS-2B PGC-1 TFAM E-cadherin
western blot n=3
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HDM (μg/ml) 0 1 10 100 200
0 0 12 12 24 484824
β-actin
Time (hours)HDM concentration (μg/ml)
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(1 μM) ー ー
＋ ＋ SRT1720(1 μM)
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control HDM
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control HDM
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